Gilead reports data for HIV regimen containing tenofovir prodrug

Gilead Sciences Inc. (NASDAQ:GILD) reported data from a Phase II trial to treat HIV-1 infection showing that a tenofovir alafenamide fumarate (TAF)-based HIV regimen met the primary endpoint of non-inferiority to Gilead's Stribild in treatment-naïve patients. Specifically, a single-tablet regimen of TAF plus elvitegravir/ cobicistat/emtricitabine was non-inferior to Stribild elvitegravir/cobicistat/emtricitabine/tenofovir in the proportion of patients with HIV RNA levels <50 copies/mL at week 24 (87% vs. 90%). The double-blind, U.S. Phase II trial enrolled 170 patients. TAF is a prodrug of tenofovir, a nucleotide analog prodrug reverse transcriptase inhibitor. ...